Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line
- 15 August 2010
- journal article
- research article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 20 (9) , 1611-1615
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug ReactionsCurrent Drug Metabolism, 2007
- In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chlorideToxicology Letters, 2006
- Monitoring and management of antituberculosis drug induced hepatotoxicityJournal of Gastroenterology and Hepatology, 2005
- Oxidative Stress, Toxicology, and Pharmacology of CYP2E1Annual Review of Pharmacology and Toxicology, 2004
- Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced HepatitisHepatology, 2003
- Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent TuberculosisChest, 2003
- Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cellsHuman & Experimental Toxicology, 1997
- Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosisEuropean Respiratory Journal, 1996
- The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450Pharmacological Research Communications, 1980
- The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamideTubercle, 1977